1/n Many thanks @MelissaFox26 for hosting this AM @FOX26Houston on some exciting developments for new RSV vaccines. RSV = respiratory syncytial virus affecting both seniors and young children esp infants and premature infants. A few things… 
2/n for seniors especially those with underlying COPD or congestive heart disease at risk, but now 2 potential adult vaccines might be approved soon, one from Pfizer other GSK, think of it like your 3rd respiratory illness vaccine along with flu and pneumococcal pneumonia
3/n for infants a new maternal vaccine from Pfizer given in 3rd trimester of pregnancy provider 82% protection of newborn infants in first 3 months, and still protected after 6 months. Also there’s a new monoclonal antibody given at start of RSV season showing progress
4/n then there are additional RSV vaccines in development from Moderna (mRNA) and Novavax, possibly others so I’m expecting exciting developments, which will overcome a past failure in the early 1960s using a whole inactivated virus approach that resulted in immune enhancement
5/n the downside? I don’t think these vaccines will be low cost making those perfusion F glycoproteins usually is not done vis microbial fermentation like our @TexasChildrens Covid vaccines. So I’m anticipating big time equity issues.
Meet the new boss, same as the old boss…
Meet the new boss, same as the old boss…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
